Based on the Travere Therapeutics Inc stock forecast from 14 analysts, the average analyst target price for Travere Therapeutics Inc is USD 20.32 over the next 12 months. Travere Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Travere Therapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Travere Therapeutics Inc’s stock price was USD 18.25. Travere Therapeutics Inc’s stock price has changed by +2.99% over the past week, +0.88% over the past month and +209.85% over the last year.
No recent analyst target price found for Travere Therapeutics Inc
No recent average analyst rating found for Travere Therapeutics Inc
Company Overview Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read Less
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in th...Read More
Frequently Asked Questions About Travere Therapeutics Inc (TVTX) Stock
Based on ratings from 14 analysts Travere Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 26 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on TVTX's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for TVTX is USD 20.32 over the next 12 months. The maximum analyst target price is USD 41 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on TVTX's stock to indicate if its overvalued.
The last closing price of TVTX's stock was USD 18.25.
The most recent market capitalization for TVTX is USD 1.59B.
Based on targets from 14 analysts, the average taret price for TVTX is projected at USD 20.32 over the next 12 months.
This means that TVTX's stock price may go up by +11.35% over the next 12 months.
We can't find any ETFs which contains Travere Therapeutics Inc's stock.
As per our most recent records Travere Therapeutics Inc has 380 Employees.
Travere Therapeutics Inc's registered address is 3611 Valley Centre Drive, San Diego, CA, United States, 92130.
You can get more information about it from Travere Therapeutics Inc's website at https://www.travere.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Travere Therapeutics Inc (TVTX) Stock
Based on ratings from 14 analysts Travere Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 26 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on TVTX's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for TVTX is USD 20.32 over the next 12 months. The maximum analyst target price is USD 41 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on TVTX's stock to indicate if its overvalued.
The last closing price of TVTX's stock was USD 18.25.
The most recent market capitalization for TVTX is USD 1.59B.
Based on targets from 14 analysts, the average taret price for TVTX is projected at USD 20.32 over the next 12 months.
This means that TVTX's stock price may go up by +11.35% over the next 12 months.
We can't find any ETFs which contains Travere Therapeutics Inc's stock.
As per our most recent records Travere Therapeutics Inc has 380 Employees.
Travere Therapeutics Inc's registered address is 3611 Valley Centre Drive, San Diego, CA, United States, 92130.
You can get more information about it from Travere Therapeutics Inc's website at https://www.travere.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TVTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
